BridgeMD
New treatment option for Gynecologic Cancer
Official title CARE Tool Study Aim 3
ClinicalTrials.gov ID: NCT07296887
What this study is testing
- What it's testing
- This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- for Implementation champions:
- \- Members of the cancer care team (e.g., physicians, nurses, research coordinators, financial navigators, social workers) that work with patients...
You likely can't join if
- for Implementation champions:
- Implementation champions are ineligible if they are non-employees of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert...
- Do not treat patients for gynecologic, prostate, lung, or colorectal cancer Inclusion Criteria for Patients:
- Age 18 and over
- Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months
- Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
See the full eligibility criteria
- for Implementation champions:
- \- Members of the cancer care team (e.g., physicians, nurses, research coordinators, financial navigators, social workers) that work with patients receiving treatment for gynecologic, lung, prostate, or colorectal...
- for Implementation champions:
- Implementation champions are ineligible if they are non-employees of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
- Do not treat patients for gynecologic, prostate, lung, or colorectal cancer Inclusion Criteria for Patients:
- Age 18 and over
- Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months
- Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
- Self-reported ability to read and speak English Exclusion Criteria for Patients:
- Under the age of 18
- Not diagnosed with gynecologic, prostate, lung, or colorectal cancer within the previous 12 months from recruitment
- Not receiving care at Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
- Cannot give consent due to cognitive or emotional barriers
The study team makes the final eligibility decision.
Where it's taking place
- Alton, Illinois, United States
- Rolla, Missouri, United States
- St Louis, Missouri, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Alton, Illinois, United States; Rolla, Missouri, United States; St Louis, Missouri, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.